Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2006, p. 1887-1891, Vol. 44, No. 5
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.5.1887-1891.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead, New South Wales, Australia,1 Department of Cell and Molecular Biology, Faculty of Science, University of Technology, Sydney, New South Wales, Australia,2 School of Biotechnology and Biomolecular Sciences, The University of New South Wales, New South Wales, Australia,3 Wuhan First Hospital, Hubei Province, Wuhan 430022, People's Republic of China4
Received 11 November 2005/ Returned for modification 28 January 2006/ Accepted 27 February 2006
|
|
|---|
|
|
|---|
Multiplex PCR-based reverse line blot hybridization (mPCR/RLB) is a promising method for simultaneous detection and genotyping of microorganisms, which we have used previously in several applications (5, 9, 10). In the present study we applied it to identification of the 23 S. pneumoniae serotypes represented in the polysaccharide vaccine (Pneumovax 23; Merck & Co, Inc.).
The design of primers and probes was based on recently published full cps gene cluster sequences of all 90 pneumococcal serotypes (http://www.sanger.ac.uk/Projects/S_pneumoniae/CPS/) and others available in GenBank (3, 6; F. Kong, G. L. Gilbert, L. Wang, D. Liu, and J. Tao, 13 April 2004, Australian Patent Office). For the mPCR, we modified the primers we had used previously for serotype-specific PCR for the 23 vaccine serotypes (3, 6; Kong et al., Australian Patent Office) and a published S. pneumoniae-specific primer (7). For the RLB, we designed two probes for each of the 23 serotypes, as well as two S. pneumoniae-specific control probes (Table 1). Probes and primers were designed to have similar physical characteristics so as to allow simultaneous amplification and hybridization in a multiplex reaction system (5); they were synthesized by Sigma-Aldrich (Sydney, Australia). Primers were biotinylated at the 5' end and probes had a 5'-amine group (5).
|
View this table: [in a new window] |
TABLE 1. Oligonucleotide primers and probes for multiplex PCR-based reverse line blot assay used in this study
|
RLB hybridization was based on previously published methods (http://www.nioo.knaw.nl/cl/me/) (8, 11) with the following modifications: the hybridization temperature was 60°C, and 1.25 pM of each probe, in 150 µl of 500 mM NaHCO3 (pH 8.4), was used in each slot to label the membrane (Fig. 1).
![]() View larger version (24K): [in a new window] |
FIG. 1. mPCR/RLB results for a representative sample of 43 clinical isolates. See Table 1 for descriptions and specificities of probes listed at left. The choice of probes for this membrane, in addition to two pairs of S. pneumoniae-specific probes, was based on two for each of the serotypes represented in the 11-valent conjugate vaccine (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F [shown in the top half of the membrane]) and others that are identified relatively commonly (serotypes 8, 9N, 19A, 20, and 33F) and single probes for each of the less common serotypes among those represented in the 23-valent vaccine (serotypes 2, 10A, 11A, 12, 15B, 17F, and 22F). The conventional serotypes of the 43 isolates shown on this membrane are (from left to right): 14, NT, 19F, NT, 19F, 22F, 9V, 6A, 19F, 18C, NSP, 19F, 16F, 11A, 4, 19F, 19F, 19F, 19F, 6B, 10A, 19F, 23F, 19F, 23F, 19A, 23F, 6A, 6B, 9V, 3, 14, 19F, 6B, 11A, 6A, 14, 23F, 19F, 46, 47F, 47A, and 48. NT, nontypeable. NSP, not S. pneumoniae.
|
All of the putative serotype-specific primers or probes yielded mPCR products and RLB signals from isolates with the corresponding serotypes. However, as demonstrated previously, serotype discrimination based solely on the wzy gene (or even the whole cps gene cluster) is not straightforward (3, 6). Primers and probes designed to identify serotypes 6B, 7F, 9N, 9V, 10A, 11A, 12F, 15B, 18C, 22F, and 33F could not distinguish between the target and one or more closely related serotypes, usually but not always in the corresponding serogroup (Table 1 and Fig. 1) because they share virtually identical wzy sequences. Thus, 17 serotypes, in addition to those in the 23-valent polysaccharide vaccine, were amplified and hybridized by the mPCR/RLB system. These cross-reactions are predictable, and individual serotypes can be identified using a limited number of factor antisera. The remaining 12 primer pairs and probe pairs were truly serotype specific, and there was excellent agreement between paired probes for the same serotypes, indicating that single probes would be adequate for most serotypes.
The method was further evaluated using 268 clinical isolates, the serotypes of which were unknown at the time of mPCR/RLB testing. These isolates included 135 consecutive invasive isolates referred to the NSW Pneumococcal Reference Laboratory for serotyping and 133 colonizing isolates from patients with respiratory infections at the Children's Hospital, Westmead, New South Wales, Australia. Conventional serotyping was performed using the Quellung reaction, as previously described (3). Two isolates were not amplified by mPCR/RLB, and phenotypic retesting showed that they were not S. pneumoniae. Of 266 pneumococcus strains, 12 (4.5%) were nontypeable by mPCR/RLB (amplified by mPCR but hybridized only with the pneumococcal control probe); of these, 10 belonged to serotypes not represented in the current mPCR/RLB assay, namely, 16F (one isolate), 23A (three isolates), 35F (four isolates), 35B (one isolate), and 38 (one isolate), and 2 were not serotypeable. Another 4 of the 266 pneumococcus isolates were not serotypeable but were identified by mPCR/RLB as serotype(s) 4, 11A/11D, 14, and 33F/33A/37. The predicted serotype(s) of the other 250 isolates were as follows: 3 (5 isolates), 4 (13 isolates), 6B/6A (45 isolates), 7F/7A (1 isolate), 9V/9A (15 isolates), 10A/10B (2 isolates), 11A/11D (2 isolates), 14 (51 isolates), 15B/15C (4 isolates), 18 (14 isolates), 19F (63 isolates), 19A (12 isolates), 22F/22A (2 isolates), and 23F (21 isolates). Thus, 181 of 254 (71%) isolates that were typeable by mPCR/RLB were identified exactly, and another 73 (29%) were identified to within one to five serotypes, for which a limited number of antisera were needed to distinguish individual serotypes.
Three isolates identified by mPCR/RLB as serotypes 19A, 9V/9A, and 23F had been serotyped, initially, as 19F, 19A, and 6B, respectively. The discrepancies were resolved by repeating the serotyping, which confirmed that the mPCR/RLB results were correct.
Our molecular serotype prediction mPCR/RLB assay for 23 pneumococcal "vaccine" serotypes is clearly less discriminatory than conventional serotyping (1-3, 6; Kong et al., Australian Patent Office) because individual serotype-specific targets are not available within cps gene clusters of some serotypes. However, there are obvious advantages of the mPCR/RLB. First, it uses reagents and techniques that are available in many microbiology laboratories; an uncomplicated, rapid DNA preparation method (4); and a single mPCR/RLB reaction (5). Second, it provides more consistent and objective results than immunological methods such as the Quellung reaction; cross-reactions are predictable and can be resolved with a small number of antisera. Serotypes that are nontypeable by the mPCR/RLB are isolated uncommonly from clinical specimens (
5% of invasive isolates in NSW in the past 3 years [data not shown]). Third, the method, potentially, could to be used directly to test clinical specimens and so rapidly identify possible vaccine failure.
Currently, there is no single, ideal technique for pneumococcal serotyping, but this mPCR/RLB format is convenient, rapid, objective, reproducible, and discriminatory when used in conjunction with a limited number of antisera.
This study was funded, in part, by the National Centre for Immunization Research and Surveillance of Vaccine Preventable Disease, Children's Hospital at Westmead, New South Wales, Australia.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»